INTRODUCTION {#sec1-1}
============

A symposium on liver disease was held in Jeddah on 8-9 J. Thani 1413, 2nd and 3rd of December 1992 at King Abdulaziz Hospital. I attended that symposium and gathered an extensive amount of valuable facts in medicine that I would like to share with all of my physician colleagues involved in hospitals and primary health care centers in Saudi Arabia.

The first session of that symposium was about hepatocellular carcinoma. Primary hepatocellular carcinoma (HCC) remains a major problem in developing countries, and is more prevalent in hepatitis B carriers. It is one of the tumors with the greatest malignancy and the highest mortality.

The first session of the symposium, was about a study conducted in Jeddah about HCC and the second session was on its prevention. The study strongly reinforced the role of hepatitis B and C in the development of liver carcinoma in Saudi Arabia where males at the peak age of 37 years were more susceptible. Patients usually present at a late stage with abdominal pain, abdominal distension, jaundice, portal vein thrombosis, and haematuria. There is little left to offer such patients since by the time the clinical manifestations become obvious the tumour would have already metastasized and become inoperable. However, if the tumor is detected early when HCC is still asymptomatic it is potentially curable by surgery. At this stage, the successful resection rate of small tumours is high. Diagnostic investigation of HCC includes sonography and computerised tomography scans (CT Scan).

The Causative Factors of HCC are: {#sec2-1}
---------------------------------

Chronic hepatitis -- B infectionLiver cirrhosis of any typeHepatitis -- C infectionRelation to alpha--toxin and to contraceptive pills and to high doses of diethyl estradiol and other steroids.

Primary prevention should be the goal. This involves hepatitis -- B (HBV) vaccination and possibly in the near future, a vaccination against hepatitis C.

HBV vaccine has been shown to provide excellent protection against the disease and therefore prevents HB2Ag carrier state which results in chronic liver disease and HCC.

In addition to vaccination, HCC prevention programs should include the screening of blood and blood products for hepatitis B and C viruses before transfusion; an increase in public awareness and health education about hepatitis B and C and their relation with HCC.

Since clinical presentation is too late to afford the patient much chance of recovery the outcome of the disease could be greatly altered by early detection and diagnosis by means of the serological markers.

The HCC serology markers are: {#sec2-2}
-----------------------------

Serum Alfa-fetoprotein (AFP) level in bloodGTT iso-enzyme II

Both are sensitive tests and their sensitivity could be increased if the two tests are combined.

The sudden rise in AFP is significant and should alert the clinician for the early detection of HCC cases in hepatitis B carriers.

Since AFP serology test is sensitive and not expensive, it should be used in the screening of HCC in hepatitis B carriers. The objective of conducting the AFP screening test is to detect HCC as early as possible. A single test is therefore inadequate. It should be performed periodically for hepatitis B carriers, to ensure the early detection of HCC, that is, as soon as it develops. HCC would be better managed at this early stage when surgery is effective and the prognosis of such a highly malignant carcinoma is good.

Since primary health care is the first medical facility that the patient has access to and the goal of the HCC management is prevention rather than treatment, primary health care can participate enormously in the prevention of HCC. It is therefore, of vital importance to conduct the screening of the hepatitis B carrier routinely and periodically using serum levels of AFP, to identify suspectible cases and apply the other diagnostic procedures to them. Such patients will have the opportunity of early treatment during the asymptomatic stage rather than wait till the presenting symptoms have become extreme, when the outcome is invariably poor.

In summary, HCC is common in hepatitis B carriers and the AFP test is an important screening procedure for them.

RECOMMENDATIONS {#sec1-2}
===============

Since there is a significant number of hepatitis B carriers in Saudi Arabia who are a high risk group for HCC, the following are recommended:

Initiation of a screening program for HCC through AFP blood level test in Saudi Arabia.Routine and Periodic screening of hepatitis B carriers with the AFP test.Test the hepatitis B carriers attending primary health care centers as well as hospital, in order to achieve the aim of early detection and management of HCC in Saudi Arabia.
